Shield Therapeutics (LON:STX) Sets New 1-Year High - Still a Buy?

Key Points

• Shield Therapeutics shares reached a new 52-week high, trading at GBX 6.50 ($0.09), marking a significant increase from a previous close of GBX 5.61 ($0.08).
• The company's market capitalization stands at £60.69 million, with a PE ratio of -1.58 and a notably high debt-to-equity ratio of 3,691.50.
• Shield Therapeutics specializes in pharmaceuticals, providing Accrufer®/Feraccru® to address iron deficiency in patients, which has been recently launched in the U.S.

Shield Therapeutics plc (LON:STX - Get Free Report)'s stock price hit a new 52-week high during trading on Monday . The company traded as high as GBX 6.50 ($0.09) and last traded at GBX 6.15 ($0.08), with a volume of 5994874 shares traded. The stock had previously closed at GBX 5.61 ($0.08).

Shield Therapeutics Trading Up 15.4%

The business's fifty day simple moving average is GBX 4.01 and its 200 day simple moving average is GBX 3.24. The company has a current ratio of 1.05, a quick ratio of 2.16 and a debt-to-equity ratio of 3,691.50. The stock has a market cap of £81.42 million, a P/E ratio of -2.13 and a beta of 1.42.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.